February 26, 2026 · Phase 3 readout
NVS Phase 3 readout: a positive outcome, +1.1%
+1.1%Novartis AG (NVS) →
On February 26, 2026, TQJ230 — Novartis AG (Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +1.1% in the window around the event. It had already run +15.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$166.85
1d before
$165.51
Event day
$168.62
1d after
$166.87
5d after
Pre-catalyst setup
+15.1%
30-day run-up
2030%
30-day volatility
1.6×
volume spike